Oral News and Research

RSS

New polymer additives enhance ability of oral drugs to reach bloodstream

All too often, when a person takes a pill full of a potent and effective drug, the drug passes straight through the body, not reaching the organ where it is needed — a waste of money and inconvenient if it is a cold medicine, but potentially dire if it is a treatment for a serious illness.

28 Aug 2013

Personalised management: The only way to close mortality gap for AF patients

Personalised management is the only way to close the mortality gap for patients with atrial fibrillation, according to an ESC consensus paper presented at ESC Congress 2013 by Professor Paulus Kirchhof (UK).

27 Aug 2013

University of Utah started construction on Ray and Tye Noorda Oral Health Education Building

The University of Utah on Friday, Aug. 23, 2013, broke ground on the $36.4 million Ray and Tye Noorda Oral Health Education Building, which when completed in December 2014 will house the University's new School of Dentistry.

27 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Powerful new option for treating vasculitis

In a study published in the New England Journal of Medicine, a research consortium that includes the University of Alabama at Birmingham (UAB) has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

27 Aug 2013

Review Article examines FMT methodology as effective treatment for C. difficile infection

Fecal microbiota transplantation has emerged as a highly effective treatment for recurrent Clostridium difficile infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal and non-GI diseases.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

MicuRx Pharmaceuticals raises $25 million in Series B financing

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

22 Aug 2013

In dynamic mind-body interaction, brain recruits cells from immune system to promote anxiety

New research shows that in a dynamic mind-body interaction during the interpretation of prolonged stress, cells from the immune system are recruited to the brain and promote symptoms of anxiety.

22 Aug 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

DFID awards 5-year grant to DNDi to advance research and development for neglected diseases

The UK Department for International Development (DFID) has announced its renewed support to the Drugs for Neglected Diseases initiative (DNDi), allocating a total of - 30 million (- 35 million) over the coming five years (2013-2018) to DNDi's Research & Development (R&D) portfolio to fight neglected diseases.

22 Aug 2013

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.

22 Aug 2013

Alarm therapy or drug therapy may solve bedwetting problems in children

Bedwetting affects up to 20 percent of five year olds—the age when most children have learned bladder control—and can result in an array of stressful and embarrassing social, emotional and psychological problems.

21 Aug 2013

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

21 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Otolaryngologists to present newest specialty research in OTO EXPO

The 2013 Annual Meeting & OTO EXPOSM of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 29 - October 2, at the Vancouver Convention Centre in Vancouver, BC, Canada.

17 Aug 2013

Diabetic patients taking oral fluoroquinolones may have high risk of severe blood sugar-related problems

Diabetic patients taking oral fluoroquinolones, a frequently prescribed class of antibiotics, were found to have a higher risk of severe blood sugar-related problems than diabetic patients taking other kinds of antibiotics, according to a recent study from Taiwan published in Clinical Infectious Diseases.

16 Aug 2013

Surgeons evaluate combined surgery technique to remove cancerous tumors from rectum

Surgeons at the University of California, San Diego School of Medicine are evaluating a new, combined surgery technique to remove cancerous tumors from the rectum. The hybrid technique uses the body's natural opening to remove malignancies and diseased tissue while also performing reconstruction.

16 Aug 2013

Researchers discover how common oral bacterium can contribute to colorectal cancer

Researchers from Case Western Reserve University School of Dental Medicine have discovered how a common oral bacterium can contribute to colorectal cancer, a finding that opens promising new research avenues for the development of approaches to prevent and treat the disease.

16 Aug 2013

UCLA receives $5M from NIH to develop tool for detecting stomach cancer

Imagine having a sample of your saliva taken at the dentist's office, and then learning within minutes whether your risk for stomach cancer is higher than normal. That futuristic-sounding scenario may actually not be too far from reality.

16 Aug 2013

Oral News and Research

New polymer additives enhance ability of oral drugs to reach bloodstream

Personalised management: The only way to close mortality gap for AF patients

University of Utah started construction on Ray and Tye Noorda Oral Health Education Building

FDA grants Priority Review designation to sNDA for Nexavar tablets

Powerful new option for treating vasculitis

Review Article examines FMT methodology as effective treatment for C. difficile infection

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

MicuRx Pharmaceuticals raises $25 million in Series B financing

In dynamic mind-body interaction, brain recruits cells from immune system to promote anxiety

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

DFID awards 5-year grant to DNDi to advance research and development for neglected diseases

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Alarm therapy or drug therapy may solve bedwetting problems in children

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Otolaryngologists to present newest specialty research in OTO EXPO

Diabetic patients taking oral fluoroquinolones may have high risk of severe blood sugar-related problems

Surgeons evaluate combined surgery technique to remove cancerous tumors from rectum

Researchers discover how common oral bacterium can contribute to colorectal cancer

UCLA receives $5M from NIH to develop tool for detecting stomach cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News